Baltimore biotech WindMIL Therapeutics raises $32.5 million

Baltimore biotechnology firm WindMIL Therapeutics has raised a $32.5 million to support clinical trials and further development for new cancer therapies. The Series B round was led by QiMing USA Venture Partners, the new U.S. entity of China firm QiMing. WindMIL, a cell therapy company, is previously backed by about $11 million in funding. WindMIL was founded out of Johns Hopkins University by researchers Kimberly Noonan and Dr. Ivan Borrello. Th e clinical stage company is working to develop…
Source: bizjournals.com Health Care:Physician Practices headlines - Category: American Health Authors: Source Type: news

Related Links:

Publication date: Available online 8 May 2018Source: Biochimica et Biophysica Acta (BBA) - BioenergeticsAuthor(s): L. Dard, N. Bellance, D. Lacombe, R. RossignolAbstractThe RAS pathway is a highly conserved cascade of protein-protein interactions and phosphorylation that is at the heart of signalling networks that govern proliferation, differentiation and cell survival. Recent findings indicate that the RAS pathway plays a role in the regulation of energy metabolism via the control of mitochondrial form and function but little is known on the participation of this effect in RAS-related rare human genetic diseases. Germline...
Source: Biochimica et Biophysica Acta (BBA) Bioenergetics - Category: Biochemistry Source Type: research
The Global Burden of Disease (GBD) project provides longitudinal analysis of the global burden of otolaryngologic diseases by measuring the all-cause mortality, years of life lost, the years of life lived with disability, and disability-adjusted life years. Hearing loss burden is assessed overall and as sequelae of other diseases, such as otitis media or meningitis. Using these measures, we can appreciate the high prevalence and disability related to hearing loss globally. Other otolaryngologic diseases that contribute to the GBD include otitis media, cleft lip and palate, head and neck cancer, facial trauma, and oral disorders.
Source: Otolaryngologic clinics of North America - Category: ENT & OMF Authors: Source Type: research
Publication date: Available online 8 May 2018 Source:Biochimica et Biophysica Acta (BBA) - Bioenergetics Author(s): L. Dard, N. Bellance, D. Lacombe, R. Rossignol The RAS pathway is a highly conserved cascade of protein-protein interactions and phosphorylation that is at the heart of signalling networks that govern proliferation, differentiation and cell survival. Recent findings indicate that the RAS pathway plays a role in the regulation of energy metabolism via the control of mitochondrial form and function but little is known on the participation of this effect in RAS-related rare human genetic diseases. Germline muta...
Source: Biochimica et Biophysica Acta (BBA) Bioenergetics - Category: Biochemistry Source Type: research
Abstract The RAS pathway is a highly conserved cascade of protein-protein interactions and phosphorylation that is at the heart of signalling networks that govern proliferation, differentiation and cell survival. Recent findings indicate that the RAS pathway plays a role in the regulation of energy metabolism via the control of mitochondrial form and function but little is known on the participation of this effect in RAS-related rare human genetic diseases. Germline mutations that hyperactivate the RAS pathway have been discovered and linked to human developmental disorders that are known as RASopathies. Individua...
Source: Biochimica et Biophysica Acta - Category: Biochemistry Authors: Tags: Biochim Biophys Acta Source Type: research
by Uta Meyer zum B üschenfelde, Laura Isabel Brandenstein, Leonie von Elsner, Kristina Flato, Tess Holling, Martin Zenker, Georg Rosenberger, Kerstin Kutsche RIT1 belongs to the RAS family of small GTPases. Germline and somaticRIT1 mutations have been identified in Noonan syndrome (NS) and cancer, respectively. By using heterologous expression systems and purified recombinant proteins, we identified the p21-activated kinase 1 (PAK1) as novel direct effector of RIT1. We found RIT1 also to directly interact with the RHO GTPases CDC42 and RAC1, both of which are crucial regulators of actin dynamics upstream of PAK1. The...
Source: PLoS Genetics - Category: Genetics & Stem Cells Authors: Source Type: research
Authors: Bosi A, Zanellato S, Bassani B, Albini A, Musco A, Cattoni M, Desio M, Nardecchia E, D'Urso DG, Imperatori A, Dominioni L, Noonan DM, Mortara L, Bruno A Abstract Natural killer (NK) cells are crucial in tumor recognition and eradication, but their activity is impaired in cancer patients, becoming poorly cytotoxic. A particular type of NK cells, from the decidua, has low cytotoxicity and shows proangiogenic functions. We investigated whether NK cells from peripheral blood (PB) and pleural effusions of patients develop decidual-like NK phenotype and whether exposure to IL-2 can restore their killing ability ...
Source: Journal of Immunology Research - Category: Allergy & Immunology Tags: J Immunol Res Source Type: research
Abstract OBJECTIVES: To determine the relationship among gait, grip strength, cognition, depression, pain, and fatigue, and to identify which variables are most predictive of poor sleep. SAMPLE & SETTING: 60 women with breast cancer aged 69 years or older who were receiving treatment in the Senior Adult Oncology Program at the James Cancer Hospital at the Ohio State University. METHODS & VARIABLES: The variables were gait and grip strength (functional domains), cognition, depression, pain, and fatigue. Patients were tested using the Timed Up and Go Test (TUG), Jamar Hydraulic Hand Dynamometer, Mi...
Source: Oncology Nursing Forum - Category: Nursing Authors: Tags: Oncol Nurs Forum Source Type: research
Carnitines play an important role in the energy exchange in cells, involved in the transport of fatty acids across the inner mitochondrial membrane. L-Acetylcarnitine (ALCAR) is an acetic acid ester of carnitine that has higher bioavailability than carnitine and is considered a fat-burning energizer supplement. We previously found that in serum samples from prostate cancer (PCa) patients, 3 carnitine family members were significantly decreased, suggesting a potential protective role of carnitine against PCa.
Source: Cancer Letters - Category: Cancer & Oncology Authors: Tags: Original Articles Source Type: research
Adriana Albini, Antonino Bruno, Barbara Bassani, Gioacchino D ’Ambrosio, Giuseppe Pelosi, Paolo Consonni, Laura Castellani, Matteo Conti, Simone Cristoni, Douglas M. Noonan
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Statin use is associated with lower risk of lethal prostate cancer, but contributing mechanisms are unknown. Herein, using data from the Health Professionals Follow-up Study (HPFS), we updated our previous analysis of statins and lethal prostate cancer with a decade of additional follow-up, and incorporated immunohistochemistry (IHC)-based biomarkers and gene expression profiling to identify putative mechanisms contributing to the association.
Source: The Journal of Urology - Category: Urology & Nephrology Authors: Tags: Prostate Cancer: Epidemiology & Natural History I Source Type: research
More News: American Health | Biotechnology | Cancer | Cancer & Oncology | Cancer Therapy | China Health | Clinical Trials | Funding | Health Management | John Hopkins University | Noonan Syndrome